Chemomab Therapeutics Ltd.
CMMB
$2.69
-$0.06-2.18%
NASDAQ
| 06/30/2026 | 12/31/2025 | 06/30/2025 | 03/31/2025 | 03/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -- | -- | 3.65M | 3.51M | 11.14M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | -- | 12.67M | 14.18M | 32.26M |
| Operating Income | -- | -- | -12.67M | -14.18M | -32.26M |
| Income Before Tax | -- | -- | -11.83M | -13.40M | -31.81M |
| Income Tax Expenses | -- | -- | -- | -- | -513.00K |
| Earnings from Continuing Operations | -- | -- | -11.83 | -13.40 | -31.30 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -- | -11.83M | -13.40M | -31.30M |
| EBIT | -- | -- | -12.67M | -14.18M | -32.26M |
| EBITDA | -- | -- | -12.61M | -14.12M | -32.20M |
| EPS Basic | -- | -- | -188.88 | -241.71 | -55.51 |
| Normalized Basic EPS | -- | -- | -0.61 | -1.03 | -1.76 |
| EPS Diluted | -- | -- | -188.88 | -241.71 | -55.51 |
| Normalized Diluted EPS | -- | -- | -0.61 | -1.03 | -1.76 |
| Average Basic Shares Outstanding | -- | -- | 20.59M | 18.38M | 45.16M |
| Average Diluted Shares Outstanding | -- | -- | 257.20K | 229.50K | 2.26M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |